Fangzhou Inc
HKEX:6086
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2
7.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Fangzhou Inc
Cost of Revenue
Fangzhou Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Fangzhou Inc
HKEX:6086
|
Cost of Revenue
-ÂĄ2.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
D
|
DaShenLin Pharmaceutical Group Co Ltd
SSE:603233
|
Cost of Revenue
-ÂĄ17.7B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
LBX Pharmacy Chain JSC
SSE:603883
|
Cost of Revenue
-ÂĄ15.1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-19%
|
|
|
Yifeng Pharmacy Chain Co Ltd
SSE:603939
|
Cost of Revenue
-ÂĄ14.5B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-25%
|
|
|
Yixintang Pharmaceutical Group Co Ltd
SZSE:002727
|
Cost of Revenue
-ÂĄ11.8B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-15%
|
|
|
A
|
Anhui Huaren Health Pharmaceutical Co Ltd
SZSE:301408
|
Cost of Revenue
-ÂĄ3.1B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Fangzhou Inc
Glance View
Fangzhou, Inc. is a holding company which engages in the development of online chronic disease management platforms. The company is headquartered in Guangzhou, Guangdong and currently employs 515 full-time employees. The company went IPO on 2024-07-09. The firm operates its businesses through three segments. Comprehensive Medical Services segment is mainly engaged in provision of follow-up consultations, E-prescriptions services and pharmaceutical products and home delivery services. Online Retail Pharmacy Services segment is mainly involved in provision of healthcare products and home delivery and prescription verification or e-prescription services. Customized Content and Marketing Solutions segment is mainly involved in provision of services such as academic community services and patient community services, search engine optimization, provision of medical surveys, and distributor data integration services.
See Also
What is Fangzhou Inc's Cost of Revenue?
Cost of Revenue
-2.2B
CNY
Based on the financial report for Dec 31, 2024, Fangzhou Inc's Cost of Revenue amounts to -2.2B CNY.
What is Fangzhou Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-13%
Over the last year, the Cost of Revenue growth was -13%. The average annual Cost of Revenue growth rates for Fangzhou Inc have been -13% over the past three years .